Review article

Metoclopramide and tardive dyskinesia

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Background: Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In 2009, the FDA issued a black box warning regarding long-term or high-dose use of this medication because of the risk of developing tardive dyskinesia. Aims To review the mechanism of action and pharmacokinetic properties of metoclopramide, the risk of metoclopramide-induced tardive dyskinesia, potential mechanisms that may alter and to summarize the clinical context for appropriate use of the drug. Methods We conducted a PubMed search using the following key words and combined searches: metoclopramide, neuroleptics, tardive dyskinesia, incidence, prevalence, dopamine, receptors, pharmacokinetic, pharmacology, pharmacogenetics, DRD3 Ser9Gly polymorphism, cytochrome P450, p-glycoprotein, risk factors, gastroparesis, outcome, natural history. Results Available data show that risk of tardive dyskinesia from metoclopramide use is likely to be

Original languageEnglish (US)
Pages (from-to)11-19
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume31
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Metoclopramide
Pharmacokinetics
Drug Labeling
Gastroparesis
Dopamine Antagonists
Pharmacogenetics
Dopamine Receptors
Natural History
PubMed
Cytochrome P-450 Enzyme System
Antipsychotic Agents
Glycoproteins
Tardive Dyskinesia
Pharmacology
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Review article : Metoclopramide and tardive dyskinesia. / Rao, A. S.; Camilleri, Michael.

In: Alimentary Pharmacology and Therapeutics, Vol. 31, No. 1, 01.2010, p. 11-19.

Research output: Contribution to journalArticle

@article{4897ead3a9df440982ca669c69abddf7,
title = "Review article: Metoclopramide and tardive dyskinesia",
abstract = "Background: Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In 2009, the FDA issued a black box warning regarding long-term or high-dose use of this medication because of the risk of developing tardive dyskinesia. Aims To review the mechanism of action and pharmacokinetic properties of metoclopramide, the risk of metoclopramide-induced tardive dyskinesia, potential mechanisms that may alter and to summarize the clinical context for appropriate use of the drug. Methods We conducted a PubMed search using the following key words and combined searches: metoclopramide, neuroleptics, tardive dyskinesia, incidence, prevalence, dopamine, receptors, pharmacokinetic, pharmacology, pharmacogenetics, DRD3 Ser9Gly polymorphism, cytochrome P450, p-glycoprotein, risk factors, gastroparesis, outcome, natural history. Results Available data show that risk of tardive dyskinesia from metoclopramide use is likely to be",
author = "Rao, {A. S.} and Michael Camilleri",
year = "2010",
month = "1",
doi = "10.1111/j.1365-2036.2009.04189.x",
language = "English (US)",
volume = "31",
pages = "11--19",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Review article

T2 - Metoclopramide and tardive dyskinesia

AU - Rao, A. S.

AU - Camilleri, Michael

PY - 2010/1

Y1 - 2010/1

N2 - Background: Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In 2009, the FDA issued a black box warning regarding long-term or high-dose use of this medication because of the risk of developing tardive dyskinesia. Aims To review the mechanism of action and pharmacokinetic properties of metoclopramide, the risk of metoclopramide-induced tardive dyskinesia, potential mechanisms that may alter and to summarize the clinical context for appropriate use of the drug. Methods We conducted a PubMed search using the following key words and combined searches: metoclopramide, neuroleptics, tardive dyskinesia, incidence, prevalence, dopamine, receptors, pharmacokinetic, pharmacology, pharmacogenetics, DRD3 Ser9Gly polymorphism, cytochrome P450, p-glycoprotein, risk factors, gastroparesis, outcome, natural history. Results Available data show that risk of tardive dyskinesia from metoclopramide use is likely to be

AB - Background: Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In 2009, the FDA issued a black box warning regarding long-term or high-dose use of this medication because of the risk of developing tardive dyskinesia. Aims To review the mechanism of action and pharmacokinetic properties of metoclopramide, the risk of metoclopramide-induced tardive dyskinesia, potential mechanisms that may alter and to summarize the clinical context for appropriate use of the drug. Methods We conducted a PubMed search using the following key words and combined searches: metoclopramide, neuroleptics, tardive dyskinesia, incidence, prevalence, dopamine, receptors, pharmacokinetic, pharmacology, pharmacogenetics, DRD3 Ser9Gly polymorphism, cytochrome P450, p-glycoprotein, risk factors, gastroparesis, outcome, natural history. Results Available data show that risk of tardive dyskinesia from metoclopramide use is likely to be

UR - http://www.scopus.com/inward/record.url?scp=71449126721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71449126721&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2009.04189.x

DO - 10.1111/j.1365-2036.2009.04189.x

M3 - Article

VL - 31

SP - 11

EP - 19

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 1

ER -